{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:58:56Z","timestamp":1785581936851,"version":"3.56.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background and importance:<\/jats:title>\n                    <jats:p>Guillain\u2013Barr\u00e9 syndrome is a type of immune-mediated acute polyradiculoneuritis that is typically preceded by an unspecified infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation:<\/jats:title>\n                    <jats:p>A 6-year-old black male preliminary school student who was admitted to the paediatric ward with generalized body weakness comprising both lower and upper extremities (unable to move legs and hands as a usual motor movement), not walking alone without caregiver assistance, being unable to swallow food, blurred vision, tingling in the feet and hands, an irregular heartbeat, and severe muscular pain. The patient had quadriparesis, or muscle weakness, in all four limbs (both legs and arms). Motor examination revealed decreased muscle strength in all limbs, with a Medical Research Council score of 2\/5 in the right arm of the upper extremities and 1\/5 in the right leg of the lower extremities, and 1\/5 in the left leg of the lower extremities and 2\/5 in the left arm of the upper extremities. According to the clinical signs of Guillain\u2013Barr\u00e9 syndrome, he received 400 mg\/kg of intravenous immunoglobulin every day for 5 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical discussion:<\/jats:title>\n                    <jats:p>The immune response in Guillain\u2013Barr\u00e9 syndrome damages either myelin (acute inflammatory demyelinating polyradiculoneuritis) or the axon (acute motor axonal neuropathy, as well as acute motor and sensory axonal neuritis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this study, the patient was diagnosed with acute inflammatory demyelinating polyradiculoneuritis, a subtype of Guillain\u2013Barr\u00e9 syndrome. Intravenous immunoglobulin (400 mg\/kg per day for 5\u00a0days) was administered to him to combat the Guillain\u2013Barr\u00e9 syndrome antibodies responsible for nerve damage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000000896","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:00:26Z","timestamp":1764838826000},"page":"7578-7581","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Guillain-Barr\u00e9 Syndrome After Inactivated Poliovirus Vaccination: A Rare Clinical Case Report"],"prefix":"10.1097","volume":"87","author":[{"given":"Gudisa","family":"Bereda","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Rift Valley University, Addis Ababa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"R1-20260801","first-page":"e2511","article-title":"Post vaccination guillain barr\u00e9 syndrome: a case report","volume":"10","author":"WajihUllah","year":"2018","journal-title":"Cureus"},{"key":"R2-20260801","doi-asserted-by":"crossref","first-page":"1214\u201328","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"R3-20260801","doi-asserted-by":"crossref","first-page":"197\u2013204","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barr\u00e9 syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R4-20260801","doi-asserted-by":"crossref","first-page":"1081\u201389","DOI":"10.1001\/jamainternmed.2020.2033","article-title":"Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19","volume":"180","author":"Liang","year":"2020","journal-title":"JAMA Intern Med"},{"key":"R5-20260801","first-page":"233\u20135","article-title":"Guillain Barre syndrome associated with COVID-19 infection: a case report","volume":"76","author":"Karimi","year":"2020","journal-title":"J Clin Neurosci"},{"key":"R6-20260801","doi-asserted-by":"crossref","first-page":"2050313X19838750","DOI":"10.1177\/2050313X19838750","article-title":"Guillain\u2013Barr\u00e9 syndrome with unilateral peripheral facial and bulbar palsy in a child: a case report","volume":"7","author":"Sharma","year":"2019","journal-title":"SAGE Open Med Case Rep"},{"key":"R7-20260801","doi-asserted-by":"crossref","first-page":"123\u201333","DOI":"10.1159\/000324710","article-title":"Population incidence of GuillainBarr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"R8-20260801","doi-asserted-by":"crossref","first-page":"577294","DOI":"10.1016\/j.jneuroim.2020.577294","article-title":"Guillain-Barr\u00e9 syndrome in a patient infected with SARS-CoV-2, a case report","volume":"346","author":"Farzi","year":"2020","journal-title":"J Neuroimmunol"},{"key":"R9-20260801","first-page":"226\u2013363","article-title":"The SCARE 2020 guideline: updating consensus-based surgical case report guidelines","volume":"84","author":"Agha","year":"2020","journal-title":"Int J Surg"},{"key":"R10-20260801","doi-asserted-by":"crossref","first-page":"106413","DOI":"10.1016\/j.clineuro.2020.106413","article-title":"Guillain-Barre Syndrome and COVID-19: A case report","volume":"200","author":"Bueso","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"key":"R11-20260801","doi-asserted-by":"crossref","first-page":"5\u201316","DOI":"10.1016\/j.ejpn.2020.01.003","article-title":"Diagnosis and treatment of Guillain-Barr\u00e9 syndrome in childhood and adolescence: an evidenceand consensus-based guideline","volume":"25","author":"Korinthenberg","year":"2020","journal-title":"Eur J Paediat Neurol"},{"key":"R12-20260801","doi-asserted-by":"crossref","first-page":"1653\u201366","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"key":"R13-20260801","doi-asserted-by":"crossref","first-page":"671\u201383","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barre syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"R14-20260801","doi-asserted-by":"crossref","first-page":"341\u201342","DOI":"10.1136\/jnnp-2021-327027","article-title":"Bilateral facial weakness with paraesthesia variant of GuillainBarr\u00e9 syndrome following Vaxzevria COVID-19 vaccine","volume":"93","author":"Bonifacio","year":"2022","journal-title":"J NeurolNeurosurg Psychiatry"},{"key":"R15-20260801","doi-asserted-by":"crossref","first-page":"717\u201327","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-barre syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"R16-20260801","doi-asserted-by":"crossref","first-page":"e0151611","DOI":"10.1371\/journal.pone.0151611","article-title":"Distinct clinical characteristics of pediatric GuillainBarr\u00e9 syndrome: a comparative study between children and adults in Northeast China","volume":"11","author":"Wu","year":"2016","journal-title":"PLoS One"},{"key":"R17-20260801","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3389\/fphar.2020.01278","article-title":"COVID-19 usurps host regulatory networks","volume":"11","author":"Curran","year":"2020","journal-title":"Front Pharmacol"},{"key":"R18-20260801","doi-asserted-by":"crossref","first-page":"e010651","DOI":"10.1136\/bmjopen-2015-010651","article-title":"SCISSOR\u2014Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol","volume":"6","author":"Kopp","year":"2016","journal-title":"BMJ Open"},{"key":"R19-20260801","doi-asserted-by":"crossref","first-page":"1626\u201335","DOI":"10.1016\/j.jtho.2017.08.007","article-title":"Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors","volume":"12","author":"Feng","year":"2017","journal-title":"J Thorac Oncol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000000896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:10:28Z","timestamp":1785579028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000000896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000000896","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"2023-04-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}